Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.
AstraZeneca stock has delivered a 73.3% total return over the past five years, and both the intrinsic value estimate using a Discounted Cash Flow (DCF) approach and the market multiples currently point to the shares trading below that intrinsic value. At the same time, AstraZeneca only scores in the middle of the pack on broader valuation checks, so the gap between price and estimated value deserves a closer look.
Over five years, a 73.3% return suggests AstraZeneca has already rewarded long term holders. This puts more focus on whether there is still a margin between the current price and intrinsic value.
Positive regulatory momentum for Enhertu in HER2 positive metastatic breast cancer can support expectations for future cash flows. The risk is that pipeline setbacks or trial failures temper those expectations and narrow any perceived discount.
The company screens as undervalued on both the Discounted Cash Flow (DCF) estimate and earnings multiples, yet its broader checks are mixed, with AstraZeneca scoring 4 out of 6 on valuation. This points to some support for value but not an across the board bargain.
The issue now is whether the current discount suggested by intrinsic value and multiples gives AstraZeneca investors enough comfort given the mixed overall valuation score.
Find out why AstraZeneca’s 18.0% return over the last year is lagging behind its peers.
Does AstraZeneca Look Undervalued on Cash Flow?
The Discounted Cash Flow (DCF) method values AstraZeneca based on the cash it is expected to generate for shareholders. AstraZeneca’s latest twelve month free cash flow is about US$7.6b, and the model assumes that these cash flows continue to grow rather than shrink over time. On that basis, the DCF points to an estimated intrinsic value of about £227 per share.
Set against the current share price, this implies roughly a 43.0% discount, so the stock screens as undervalued on this measure. The recent Enhertu recommendation for first line HER2 positive metastatic breast cancer in the EU is one factor that supports the cash flow forecasts used in the model, while the market price remains below the DCF output.
On the cash flow numbers used here, AstraZeneca stock currently looks undervalued relative to its DCF based intrinsic value estimate.
Our Discounted Cash Flow (DCF) analysis suggests AstraZeneca is undervalued by 43.0%. Track this in your watchlist or portfolio, or discover 8 more high quality undervalued stocks.
Story Continues
AZN Discounted Cash Flow as at Jul 2026
Is AstraZeneca a Bargain on Earnings?
P/E is a useful check for AstraZeneca because earnings remain a core focus for many investors in large pharmaceutical stocks. AstraZeneca currently trades on a P/E of about 25.5x, which is higher than the Pharmaceuticals industry average of 20.8x and also above the peer average of 12.4x. On simple comparisons, the stock does not look cheap against either its sector or closer peers.
However, a more tailored “fair” P/E ratio that adjusts for AstraZeneca’s size, margins, sector and risk profile is estimated at around 39.6x. Against that benchmark, the current 25.5x multiple sits well below what the model suggests could be justified. This is consistent with the DCF view that the share price is not fully reflecting the company’s earnings power.
On this earnings multiple, AstraZeneca stock screens as undervalued relative to the fair P/E that the model assigns to the business.
LSE:AZN P/E Ratio as at Jul 2026
See what the numbers say about this price — find out in our valuation breakdown.
The AstraZeneca Narrative: What Would Justify Today’s Price?
Simply Wall St Narratives pick up where this AstraZeneca valuation puzzle leaves off by spelling out which assumptions on growth, margins and earnings would need to hold for the stock to be worth materially more or less than today’s price, using scenarios shared on the Community page. Rather than a single multiple or model output, each narrative lays out the key inputs behind its fair value view so you can compare those expectations with AstraZeneca’s reported results over time.
Community views on AstraZeneca sit far apart, with one side focused on pipeline upside and the other on trial risk and pricing pressure.
Bull case: 22% undervalued
“The company’s robust and diversified late-stage pipeline, particularly in oncology, rare diseases, and cardiovascular/metabolic therapies, is set to deliver multiple blockbuster launches…”
Read the full Bull Case to see why AstraZeneca could be undervalued
Bear case: 9% overvalued
“The looming expiration of patents on key blockbuster drugs like Tagrisso, Farxiga, and Imfinzi exposes AstraZeneca to biosimilar and generic competition that is almost certain to erode high-margin revenue streams…”
Read the full Bear Case to see why AstraZeneca could be overvalued
Do you think there’s more to the story for AstraZeneca? Head over to our Community to see what others are saying!
The Bottom Line
The valuation work on AstraZeneca points in the same direction. Both the Discounted Cash Flow (DCF) intrinsic value estimate and the earnings based multiples suggest the stock trades at a discount, although the broader checks are only mixed rather than emphatically supportive. For you, the key question is whether the market is being too cautious about pipeline risk, trial outcomes and patent expiries, or is correctly discounting those pressures. That tension between future cash flow delivery and the risk around the late stage portfolio is what will decide whether today’s apparent discount turns into opportunity or a value trap.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include AZN.L.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com